AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia

Recruitingn/aAges 18 Years - anyAllCentre Hospitalier Intercommunal Aix-Pertuis
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit. The main questions it aims to answer are: * evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring * search an association between immunoplegia depth and severity of the initial state of shock * search an association between immunoplegia depth and viral reactivation * compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patient over 18 years old * Patient admitted in the Intensive Care Unit of the CHIAP * Patient under mechanical ventilation * Patient with infectious pneumonia * Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives * Patient beneficiary of French social security, whatever the regime Exclusion Criteria: * Patient under 18 years old * Patient with severe neutropenia (neutrophils \< 0.5 G/L) * Patient under immunosuppressive treatment * Use of corticosteroids (intravenous or oral) prior to ICU admission * Use of therapeutic antibodies * Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion * End of chemotherapy 6 months prior to inclusion * Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage) * Patients with a decision to limit or discontinue active therapies, at the time of inclusion * Patients with an estimated ICU stay of less than 48 hours * Participation in an interventional study * Patient deprived of their liberty * Patient under tutorship or curatorship * Pregnant or breastfeeding woman
๐Ÿ’Š

What it tests

  • Blood collection
๐Ÿ“

Where

1 site
Centre Hospitalier Intercommunal Aix-Pertuis
Aix-en-Provence, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy